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Cardiovascular complications are the most important cause
of death in patients on dialysis with end-stage renal disease.
Antibodies reacting with b-glycoprotein I seem to play a
pathogenic role in antiphospholipid syndrome and stroke
and are involved in the origin of atherosclerosis. Here
we evaluated the presence of anticardiolipin and anti-b-
glycoprotein I antibodies together with other vascular
risk factors and their relationship with mortality and
cardiovascular morbidity in a cohort of 124 hemodialysis
patients prospectively followed for 2 years. Of these,
41 patients were significantly positive for IgA anti-b-
glycoprotein I, and the remaining had normal values. At 24
months, overall and cardiovascular mortality and thrombotic
events were all significantly higher in patients with high anti-
b-glycoprotein I antibodies. Multivariate analysis using Cox
regression modeling found that age, hypoalbuminemia, use
of dialysis catheters, and IgA b-glycoprotein I antibodies were
independent risk factors for death. Thus, IgA antibodies to
b-glycoprotein I are detrimental to the clinical outcome of
hemodialysis patients.
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Cardiovascular disease in chronic kidney disease–treated
patients has a higher prevalence than in the general
population of the same age, and it is especially high in
dialyzed patients.1,2 Endothelial dysfunction is common in
end-stage renal disease and may contribute to the develop-
ment of both hypertension and atherosclerosis.3 Cardiovas-
cular complications rank first among the causes of death in
patients with chronic kidney disease and end-stage renal
disease on dialysis and include thrombotic episodes in
cerebral and myocardial vessels.4
Antiphospholipid syndrome (APS) is an autoantibody-
mediated disease in which antiphospholipid antibodies are
directed against various combinations of phospholipids,
phospholipid-binding proteins, or both.5 The most com-
monly detected subgroups of antiphospholipid antibodies are
lupus anticoagulant antibodies, anticardiolipin antibodies
(aCL), and anti-b2 glycoprotein I antibodies (aB2GPI).6
These antibodies bind to antigens localized on the mem-
branes of cells involved in the coagulation cascade: platelets,
monocytes, and endothelial cells.7 Such interaction and
interference with coagulation factors might be responsible for
the hypercoagulability observed in APS.8
Several studies have demonstrated that antiphospholipid
antibodies are more frequent in patients with chronic kidney
disease than in the general population. However, its origin is
unclear and the precise mechanisms involved in conferring
possible cardiovascular risk to it are unknown.9
Although most of the aCL in the APS syndrome bind to
the phospholipid-b2-glycoprotein I complex (B2GPI) as
cofactor,10 antibodies directed individually against B2GPI11
have been described.
B2GPI, also known as apolipoprotein H, is a 50-kDa
cationic plasma protein that presents a high affinity for
anionic phospholipids. Its plasma concentration is 200 mg/ml,
40% of which are associated with lipids.12 B2GPI has
anticoagulant properties, modulates adenosine diphosphate-
dependent activation of platelets,13 and inhibits factor XII
activation14 and prothrombinase and tenase activity on
platelets.15 It has been demonstrated that aB2GPI antibodies
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also play a pathogenic role in APS,8 stroke,16 and in the
origin of atherosclerosis.17 Authors have referred to aB2GPI
antibodies of immunoglobulin G (IgG) and IgM class in the
pathogenesis of atherosclerosis and chronic vascular disease.
However, the importance of IgA-aB2GPI has not been
reported until recently.18
The purpose of this study has been to prospectively study
end-stage renal disease patients on hemodialysis followed up
for 2 years on the prevalence of aCL and aB2GPI and their
influence on clinical outcomes.
RESULTS
A total of 148 patients on dialysis were included in the study
and were prospectively followed up for 2 years. Of these,
24 (16.2%) received a renal transplant and were excluded,
and hence 124 patients were finally included in the study
(Figure 1).
Table 1 shows the demographics and clinical character-
istics of patients; a prevalence of patients with IgA-aB2GPI
(IgA-aB2GPIþ ) stands out.
Mortality
During the follow-up, 33 (26.6%) of the patients died.
Compared with the surviving patients, those who died were
older, and had a higher incidence of ischemic cardiomyop-
athy, central catheter, hypoalbuminemia, and positivity for
the IgA-aB2GPI antibodies. Other antiphospholipid-asso-
ciated antibodies were present in the 124 patients studied:
anticardiolipin IgG (9.7%) anticardiolipin IgM (6.4%), and
aB2GPI IgG (10.9%; Table 1), but they were not found to be
related with mortality (Table 2).
Patients with IgA-aB2GPI
A total of 41 patients were IgA-aB2GPIþ (33.1%) at the
beginning and remained positive until the end of follow-up
(group 1). In addition, 83 (66.9%) were always IgA-aB2GPI
(group 2). Mortality was higher in group 1 (46.3% vs. 16.8%,
Po0.001). Patients included in group 1 were older (but not
significantly, P¼ 0.088) and had more thrombotic events
(46.3% vs. 12.0%, Po0.001) and more thrombosis on
vascular access (24.4% vs. 7.2%, P¼ 0.007) in the follow-
up study. In addition, incidence of atherosclerosis-related
vascular events (stroke, acute myocardial infarction, and
transient ischemic attack) was higher in group 1 (12.2% vs.
7.2%, P¼ 0.033). Other variables showed no differences
(Table 3).
148 Patients on dialysis
Transplanted
(excluded)
24 (16.2%)
Continue on
dialysis 24 months
124 (83.8%)
lgA anti-B2 glycoprotein
Positive : 41 (33.1%)
19 Dead
(46.3%)
Dead by CVD
12/19 (63.1%)
Dead by CVD
4/14 (28.6%)
22 Alive
(53.7%)
14 Dead
(16.9%)
69 Alive
(83.1%)
lgA anti-B2 glycoprotein
Negative : 83 (66.9%)
Figure 1 |Algorithm of disposition and outcomes.
CVD, cardiovascular disease; IgA, immunoglobulin A.
Table 1 | Distribution of patients
Studied Excluded
Mean (s.d.)/
number (%)
Mean (s.d.)/
number (%) P-value
Demographic characteristics
Number of patients 124 (83.8%) 24 (16,2%)
Time on hemodialysis
before study (months)
37.3 (30) 36.9 (31) 0.915
Age (years at begin study) 64.3 (15.6) 61.7 (14.4) 0.766
Age range 20–90 25–82
Men 82 (66.9%) 20 (83.3%) 0.110
Clinical measures
Diabetes mellitus 47 (37.9%) 10 (41.7%) 0.729
Arterial hypertension 100 (79.8%) 19 (79.1%) 0.867
Hypoalbuminemia 35 (28.2%) 6 (25.0%) 0.746
Previous transplantation 27 (21.7%) 6 (25.0%) 0.728
Central venous catheter 52 (41.9%) 8 (33.3%) 0.432
Ischemic cardiomyopathy
antecedents
39 (31.4%) 4 (16.7%) 0.144
Stroke/TIA antecedents 15 (12.0%) 4 (16.7%) 0.540
Coumarin treatment 22 (17.7%) 4 (16.7%) 0.899
Biochemical values
Cholesterol (mg/dl) 147.9 (37.3) 151.0 (32.5) 0.989
LDL-C (mg/dl) 74.3 (30.2) 80.1 (25.7) 0.463
HDL-C (mg/dl) 44.4 (12.6) 44.1 (10.2) 0.761
Triglycerides (mg/dl) 152.7 (79.7) 134.5 (45.3) 0.345
Homocysteine (mg/dl) 32.4 (15.7) 36.9 (15.8) 0.627
Immunity and inflammation
markers
IgA-aB2GPI+ 41 (33.1%) 5 (20.8%) 0.236
IgM-aB2GPI+ 3 (2.4%) 0 (0%) 0.585
IgG-aB2GPI+ 15 (12.1%) 2 (8.3%) 0.256
IgA-aCL+ 2 (1.6%) 0 (0%) 0.701
IgM-aCL+ 8 (6.4%) 3 (12.5%) 0.174
IgG-aCL+ 12 (9.7%) 2 (8.3%) 0.299
CRP+ 44 (35.4%) 8 (33.3%) 0.840
Abbreviations: aB2GPI+, patients with elevated titers of anti-b glycoprotein I of any
isotype; aCL+, patients with elevated titers of anticardiolipin of any isotype; CRP+,
patients with elevated values of C-reactive protein (41mg/dl); HDL-C, high-density
lipoprotein cholesterol; Ig, immunoglobulin; LDL-C, low-density lipoprotein choles-
terol; TIA, transient ischemic attack.
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Original diseases as causes of end-stage renal disease were
not different among groups (Table 3).
Survival at 2 years
Therefore, patient survival at 2 years was significantly lower
in group 1 (Figure 2) and, interestingly, cardiovascular
disease was significantly higher in group 1 as a cause of death
compared with group 2. Out of the total 19 deceased patients
in group 1, the cause of death in 12 (63.1%) was
cardiovascular disease, whereas in group 2, only 4 of 14
(28.5%) died because of cardiovascular disease (P¼ 0.043,
Table 4).
IgA-anti-B2GPI is an independent risk factor for death
The hazard ratio of anti-IgA-aB2GPIþ for mortality without
adjusting for other risk factors was 3.274 (95% confidence
interval, Po0.001). Notably, the hazard ratio of anti-IgA-
aB2GPIþ continued to be clearly significant (2.544; 95%
confidence interval 1.264–5.119, P¼ 0.009) in the Cox
regression model adjusted for other important variables to
predict mortality such as patient age, presence of hypoalbu-
minemia, and use of catheter for dialysis (Table 5).
DISCUSSION
Our study is the first prospective study that has shown that
the presence of IgA-aB2GPI is an independent risk factor for
death in hemodialysis patients together with other well-
known factors such as patient age, hypoalbuminemia, and
the use of central catheter for dialysis.
It has been described that the mortality rate in patients on
maintenance hemodialysis is 420% per year and cardiovas-
cular disease is the first cause of death. Age, inadequacy of
dialysis, inflammation, high levels of parathyroid hormone,
vascular access, hypoalbuminemia, and ischemic cardiomyop-
athy, together with biomarkers associated with inflamma-
tion, cardiovascular risk factors, and protein-energy wasting,
have been related with mortality in patients on hemodia-
lysis.19
Mortality in our units was 26.6% in 2 years. As expected,
cardiovascular disease was the most important cause of
death. Patients who died were more frequently older (mean
age of 72 years standing out), had a background of ischemic
cardiomyopathy and hypoalbuminemia, and had used a
central catheter for dialysis. The presence of IgA-aB2GPI
antibodies was also a significant risk factor for death. In
addition, cardiovascular mortality was significantly higher in
IgA-aB2GPIþ versus IgA-aB2GPI patients (12/19, 63.1%
vs. 4/14, 28.5%, P¼ 0.043). In group 1, no patients died from
cancer, whereas cancer-caused mortality in group 2 (negative
patients) was similar to the general population (P¼ 0.024 for
cancer-caused mortality in group 1 versus 2). This finding
should be confirmed in bigger samples of patients and
requires further investigation.
Antibodies of IgA isotype directed against B2GPI have
been previously associated with a higher risk for vascular
disease, including peripheral vascular disease, cerebral
ischemia, stroke, myocardial infarction, and with throm-
boembolic events,16,20,21 especially in patients with systemic
lupus erythematosus.22 Our results support that laboratory
criteria for APS23 might be revised to include IgA-aB2GPI
antibodies, as also suggested by other authors.21
Elevated titers of aCL and aB2GPI of IgG and IgM class in
chronic kidney disease–dialyzed subjects have been previously
described,24 but the presence of IgA-aB2GPI antibodies has
not been reported.
Interestingly, dialyzed patients who were IgA-aB2GPIþ
were negative for IgA-aCL antibodies. This suggests that IgA-
aB2GPI antibodies recognize epitopes available in free
B2GPI but not in the phospholipid-bound form. aB2GPI
antibodies of IgA isotype, but not aCL, have been associated
with macrovascular disease and mortality in scleroderma
patients.25 Two B2GPI conformations exist in serum, lineal
and circular.26 Further immunochemical studies are needed
to define the precise epitope target of IgA-aB2GPI antibodies.
B2GPI is expressed in platelets and endothelial cells,27 and
has been found in atheroma plates.28 aB2GPI antibodies,
mostly of the IgA isotype, have been described as an
independent risk factor associated with acute coronary
syndromes in young patients.29 The exact mechanism of
Table 2 | Parameters on alive and dead patients
Alive Dead
Mean (s.d.)/
number (%)
Mean (s.d.)/
number (%) P-value
Number of patients 91 (73.4%) 33 (26.6%)
Time on dialysis (months) 36.0 (32.4) 38.4 (21.6) 0.343
Age (years at begin study) 61.58 (15.8) 71.6 (12.6) o0.001
Age range 20–87 39–90
Men 61 (67.0%) 21 (63.7%) 0.638
Diabetes mellitus 31 (34.1%) 16 (48.4%) 0.143
Arterial hypertension 71 (78.0%) 29 (87.9%) 0.216
Hypoalbuminemia 18 (19.8%) 17 (51.5%) o0.001
Previous transplantation 22 (24.1%) 5 (15.1%) 0.281
Central venous catheter 29 (31.9%) 23 (69.7%) o0.001
Incidence of thrombotic
processes
20 (22.0%) 9 (27.3%) 0.538
Ischemic cardiomyopathy
antecedents
22 (24.1%) 17 (51.5%) 0.004
Stroke/TIA antecedents 8 (8.7%) 7 (18.1%) 0.061
Coumarin treatment 15 (16.5%) 7 (21.2%) 0.542
Cholesterol (mg/dl) 148.8 (33.8) 149.4 (47.6) 0.588
LDL-C (mg/dl) 76.3 (32.2) 68.1 (24.4) 0.358
HDL-C (mg/dl) 46.0 (12.1) 43.2 (14.0) 0.571
Triglycerides (mg/dl) 151.6 (73.2) 153.7 (98.0) 0.297
Homocysteine (mg/dl) 35.7 (16.5) 28.2 (14.6) 0.341
IgA-aB2GPI+ 22 (24.1%) 19 (57.5%) o0.001
IgM-aB2GPI+ 1 (1.1%) 2 (6.0%) 0.154
IgG-aB2GPI+ 10 (10.9%) 5 (15.1%) 0.191
IgA-aCL+ 2 (2.1%) 0 (0%) 0.537
IgM-aCL+ 8 (8.7%) 0 (0%) 0.077
IgG-aCL+ 11 (12.1%) 1 (3.0%) 0.098
CRP+ 30 (33.0%) 14 (42.4%) 0.331
Abbreviations: aB2GPI+, patients with elevated titers of anti-b glycoprotein I of any
isotype; aCL+, patients with elevated titers of anticardiolipin of any isotype; CRP+,
patients with elevated values of C-reactive protein (41mg/dl); HDL-C, high-density
lipoprotein cholesterol; Ig, immunoglobulin; LDL-C, low-density lipoprotein choles-
terol; TIA, transient ischemic attack.
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aB2GPI antibodies causing thrombosis and vascular disease
remains unknown, although inhibition of B2GPI anti-
coagulant activity has been suggested as a pathogenic
mechanism.30 It is not known how the immune response
against B2GPI is generated. Some infections (Helicobacter
pylori, Actinomyces, or yeast) have been claimed to trigger an
Table 3 | Differences between patients positive (group 1) and negative (group 2) for IgA-anti-B2GPI
Group 1 Group 2
IgA-aB2GPI positive IgA-aB2GPI negative
Mean (s.d.)/ number (%) Mean (s.d.)/number (%) P-value
Number of patients 41 (33.1%) 83 (66.9%)
Time on dialysis (months) 39.6 (20.4) 35.7 (21.6) 0.141
Dead in 24 months 19 (46.3%) 14 (16.8%) o0.001
Men 27 (65.8%) 55 (66.2%) 0.963
Age (years) 67.7 (12.2) 62.6 (17.1) 0.088
Age range 39–83 20–90
Diabetes mellitus 20 (48.7%) 27 (32.5%) 0.079
Arterial hypertension 34 (82.9%) 66 (79.5%) 0.651
Central venous catheter 20 (48.8%) 32 (38.5%) 0.277
Previous transplantation 8 (19.5%) 19 (22.9%) 0.668
Hypoalbuminemia 16 (39.0%) 19 (22.9%) 0.060
Ischemic cardiomyopathy antecedents 13 (31.7%) 26 (31.3%) 0.966
Stroke/TIA antecedents 6 (14.6%) 9 (10.8%) 0.542
Coumarin treatment 10 (24.4%) 12 (14.5%) 0.173
Cholesterol (mg/dl) 154.9 (36.6) 144.2 (32.9) 0.089
Triglycerides (mg/dl) 146.7 (81.0) 154.8 (79.6) 0.297
Homocysteine (mg/dl) 31.3 (18.0) 33.4 (17.4) 0.341
CRP+ 15 (36.6%) 31 (37.3%) 0.934
Incidence of thrombotic processes 19 (46.3%) 10 (12.0%) o0.001
AVF thrombosis (alone or with other thrombosis) 10 (24.4%) 6 (7.2%) 0.007
Non-AVF venous or arterial thrombosis 9 (22.8%) 4 (4.8%) 0.003
Atherosclerosis-related diseases (stroke, TIA, AMI) 5 (12.2%) 2 (2.4%) 0.033
IgM-aB2GPI+ 2 (4.9%) 1 (1.2%) 0.219
IgG-aB2GPI+ 8 (19.5%) 7 (8.4%) 0.075
IgA-aCL+ 2 (4.9%) 0 (0%) 0.107
IgM-aCL+ 2 (4.9%) 6 (7.2%) 0.616
IgG-aCL+ 2 (4.9%) 10 (12.0%) 0.204
Etiology of end-stage renal disease
Glomerular disease 8 (19.5%) 17 (20.4%) 0.899
Nephroangiosclerosis 6 (14.6%) 17 (20.4%) 0.430
Diabetic nephropathy 15 (36.5%) 19 (22.8%) 0.107
Tubulointerstitial nephritis 2 (4.8%) 10 (12%) 0.203
Others (obstructive, metabolic, and so on) 5 (12.1%) 12 (14.5%) 0.730
Undetermined 5 (12.1%) 8 (9.6%) 0.662
Abbreviations: aB2GPI+, patients with elevated titers of anti-b2 glycoprotein I of any isotype; aCL+, patients with elevated titers of anticardiolipin of any isotype; AMI, acute
myocardial infarction; AVF, arteriovenous fistula; CRP+, patients with elevated values of C-reactive protein (41mg/dl); Ig, immunoglobulin; TIA, transient ischemic attack.
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Figure 2 | Survival curves at 24 months in patients positive
(group 1) and negative (group 2) for immunoglobulin A (IgA)
anti-b2 glycoprotein I (anti-B2GPI) antibodies.
Table 4 | Causes of death in patients positive (group 1) and
negative (group 2) for IgA-aB2GPI
Group 1 Group 2
Causes of death
IgA-aB2GP+
N=19
IgA-aB2GP
N=14
P-value
(Fisher)
Vascular pathology 12 (63.1%) 4 (28.5%) 0.043
Stroke 4 1
Myocardial infarction 4 3
Heart failure 1 0
Intestinal thrombosis 2 0
Pulmonary embolism 1 0
Neoplasia 0 (0%) 4 (28.5%) 0.024
Infections 2 (10.5%) 1 (7.1%) 0.438
Others 5 (26.3%) 5 (35.7%) 0.251
Abbreviations: aB2GPI, anti-b2 glycoprotein I; IgA, immunoglobulin A.
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immune response, biased toward production of IgA,
by molecular mimicry between pathogens and B2GPI
epitopes.31
In hemodialysis patients, it can be speculated that antigens
released from endothelial cell membranes interact with
dialysis membranes forming hapten-carriers complexes.
Under the immunodeficiency state induced by uremia, these
complexes would stimulate the formation of aB2GPI
antibodies that would promote hypercoagulability and favor
the progression of atherosclerosis, which is, in turn, one of
the more frequent complications in these patients.32
In conclusion, we present an original finding, that is, the
presence of anti-IgA-aB2GPI antibodies in hemodialysis
patients could be associated with mortality and incidence
of thrombotic processes. On the basis of this study, we
suggest that testing IgA-aB2GPI in patients on dialysis may
be important to identify those at risk of thrombosis and
vascular disease. Then, a better and quick management could
be established. However, before recommending an effective
therapy in patients with IgA-aB2GPI, prospective and
multicenter studies with an elevated number of patients
demonstrating the usefulness of IgA-aB2GPI as a biomarker
of vascular disease in dialysis patients are mandatory.
MATERIALS AND METHODS
Design of the study
This work is a historical cohort study with follow-up (from
1 January 2007 to 31 December 2008). The study was approved by
the Institutional Review Board of the Hospital 12 de Octubre
(disposition algorithm and outcomes, Figure 1).
Patients
A total of 148 patients with end-stage renal disease who had been on
chronic hemodialysis for at least 9 months were included in the
study. The patients were recruited from two different dialysis units,
the Hospital 12 de Octubre and Clinica San Luciano, both units
belonging to the same Nephrology Department. Enrollment
included the total unscreened population. The patients were
prospectively followed up for 2 years. Of these patients, 24 (16%)
received a renal transplantation and were therefore excluded from
the study. The characteristics of these 24 patients did not differ from
the 124 who completed the follow-up and who were finally analyzed
(Table 1). Demographic data of the 124 patients studied were: 121
Caucasian, 1 Asian, and 2 East African.
Dialysis schedule. All patients underwent bicarbonate dialysis
using polyamide or polysulfone membranes thrice weekly. A total of
52 patients (42%) were dialyzed through a permanent tunneled
catheter.
Dialysis adequacy was quantified using fractional clearance
of urea, which is commonly expressed as Kt/V. Efficient clearance
was considered when clearance values were 41.2 Kt/V. The
dialysis schedule was modified to obtain a Kt/V of 41.2 in all
the cases.
Definitions
Cardiovascular risk factors. Arterial hypertension was defined
as systolic blood pressure 4140 mm Hg or diastolic blood pressure
490 mm Hg on repeated measurements or when the patient was
taking any antihypertensive treatment. Diabetes mellitus was
considered to be present if the patient was on insulin, oral
hypoglycemic agents, or diabetic diet, or if the patient’s fasting
glucose was 4126 mg/dl.
Cardiovascular events. A history of cardiovascular disease was
defined as ischemic cardiomyopathy (including myocardial infarc-
tion, coronary heart disease, coronary revascularization, history of
angina with abnormal coronarography, or myocardial scintigraphy),
cerebrovascular disease (acute strokes and transient ischemic attack)
or a history of carotid endarterectomy.
Thrombotic events. A past history of thrombotic event was
defined as when the patient had a history of deep venous
thrombosis, arterial thrombosis, pulmonary embolism, arteriove-
nous fistula, or vascular access thrombosis.
We have considered thrombotic episodes to exist in the 24
months of study when there was acute stroke, transient ischemic
attack, pulmonary thromboembolism, deep venous thrombosis, or
acute arterial thrombotic episodes in lower limbs. Arteriovenous
fistula thrombosis was considered independently.
Laboratory determinations
Routine laboratory determinations were performed every month,
including hematological data and biochemical serum values
(creatinine, urea, liver enzymes, glucose, cholesterol and triglycer-
ides, uric acid, calcium, phosphate, total proteins and albumin,
alkaline phosphatase, sodium, potassium, chloride, bicarbonate,
and pH).
C-reactive protein was measured along with the determination of
autoantibodies. Patients were considered as positive for C-reactive
protein when its levels were 41 mg/dl in all of the measurements.
Parathyroid hormone was measured every 3 months. For this
analysis, parathyroid hormone levels were considered at the
beginning and at the end of the study. The last available parathyroid
hormone measurement was used in the patients who had died
during the study.
Hypoalbuminemia was considered to exist if the serum albumin
was o4 g/dl in X3 measurements.
aCL and aBGPI antibodies
aCL and aBGPI antibodies were measured at the beginning of the
study and at 6 and 18 months. Autoantibodies were quantified by
enzyme-linked immunosorbent assays. The kit used to determine
IgG-aCL, IgM-aCL, IgA-aCL, IgG-aB2GPI, IgM-aB2GPI, and IgA-
aB2GPI was QUANTA Lite (INOVA Diagnostics, San Diego, CA).
Levels of antibodies 420 U/ml were considered positive (for IgG,
IgA, or IgM), according to the manufacturer’s guidelines. In the first
Table 5 |Multivariate analysis of factors associated with
death statistically significant in the univariate analysis
Variable
Hazard
ratio
95% Confidence
limits P-value
IgA-anti-B2GPI positive 2.544 1.264–5.119 0.009
Access by catheter 2.208 1.036–4.704 0.040
Age 1.027 0.998–1.057 0.073
Hypoalbuminemia 2.153 1.072–4.326 0.031
Abbreviations: aB2GPI, anti-b2 glycoprotein I; IgA, immunoglobulin A.
The association is quantified using the hazard ratio, bringing its 95% confidence
interval and its statistical significance. Positivity of IgA-ab2GPI on univariate analysis
had a hazard ratio of 3.274, with a 95% interval of 1.640–6.536 and P-value of
o0.001.
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determination, IgA-aB2GPI positivity or negativity was confirmed
using another different enzyme-linked immunosorbent assay
(ORGENTEC Diagnostika GmbH, Mainz, Germany).
Patients were considered aCLþ or aBGPIþ if the average value
of three extractions was 420 IU/ml with at least two positive
samples.
Statistical methods
Results are expressed as mean±s.d. or absolute frequency and
percentage. Association between qualitative variables was deter-
mined with w2 or Fisher’s exact test, when 425% of expected values
were o5. In variables with two categories, comparisons were
performed using Student’s t-test for independent samples.
Survival was calculated using the Kaplan–Meier Method and
differences between the distributions of survival were assessed by
log-rank test.
Death risk was also estimated by multivariate analysis using the
Cox regression model. Those mortality risk factors that were
significant in the univariate analysis (Table 2) and whose probabil-
ities werep0.001 were included in the multivariate analysis. Hazard
ratios with probabilities o0.050 were considered significant.
The statistical program STATA 11 (StataCorp LP, College Station,
TX) was used for processing and data analysis.
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